Table 1.

Clinical characteristics of the study groups

Clinical characteristics	Group 1 (partial/complete regression, n=72)	Group 2 (CIN2 progression and persistence, n=36)	p-value
Age, years (mean ± SD)	31.72±4.31	32.40±4.79	0.86
Parity, n (%)	Nulliparous: 31 (43.66%)	Nulliparous: 16 (44.44%)	0.82
Multiparous: 40 (56.33%)	Multiparous: 20 (55.55%)
Contraception, n (%)	Yes: 23 (31.94%)	Yes: 10 (27.77%)	0.77
Smokers, n (%)	Yes: 29 (40.27%)	Yes: 19 (52.77%)	0.19
Vaccination, n (%)	Yes: 13 (18.05%)	Yes: 8 (22.22%)	0.68
Previous cytology, n (%)	ASCUS: 16 (22.22%)	ASCUS: 4 (11.11%)	0.004
LSIL: 17 (23.61%)	LSIL: 8 (22.22%)
HSIL: 24 (33.33%)	HSIL: 23 (63.88%)
ASC-H: 15 (20.83%)	ASC-H: 1 (2.77%)
HPV genotyping, n (%)	HPV16: 23 (31.94%)	HPV16: 17 (47.22%)	0.003
HPV18: 5 (6.94%)	HPV18: 9 (25%)
Other HR-HPV: 43 (61.11%)	Other HR-HPV: 11 (30.55%)

ASC-H: Atypical squamous cells, cannot exclude high-grade squamous intraepithelial lesion (HSIL); ASCUS: Atypical squamous cells of undetermined significance; CIN2: Cervical intraepithelial neoplasia 2; HPV: Human papillomavirus; HR: High risk; LSIL: Low-grade squamous intraepithelial lesion; n: No. of patients; SD: Standard deviation